Overview

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Status:
Recruiting

Trial end date:
2022-07-08

Target enrollment:

Participant gender:

Summary

This study is prospective, open-label, single arm observational study to assess efficacy of obinutuzumab plus chlorambucil (GC) chemotherapy in treatment naïve CLL, and prognostic impact of genetic alterations for CLL using NGS.

Phase:

Phase 2

Details

Lead Sponsor:

Deok-Hwan Yang

Collaborator:

Roche Pharma AG

Treatments:

Chlorambucil
Obinutuzumab